Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion type Assertion NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_head.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_provenance.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion evidence source_evidence_literature NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_provenance.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion SIO_000772 22017486 NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_provenance.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion wasDerivedFrom befree-20150227 NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_provenance.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion wasGeneratedBy ECO_0000203 NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_provenance.